Team | Management Team
Stephen Dilly, M.D., Ph.D
CEO and President
Member, Board of Directors
Stephen Dilly joined APT as its CEO and president in April 2006. He has over 20 years of experience in the biotech space and is well-prepared to lead APT into its next stage of growth. Stephen previously served as the Senior Vice President of Development and Chief Medical Officer for Chiron BioPharma. He also held executive positions for Genentech and SmithKline Beecham. Throughout his career, Stephen has been closely associated with the successful development and launch of a wide array of important drugs, including: Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Stephen earned an M.D. from the University of London in 1982 and earned a Ph.D in cardiac physiology from the University of London in 1988.